Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia.
Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA, Heil G, Fenaux P, Brugger W, Barge A, O'Brien-Ewen C, Matcham J, Hoelzer D. Archimbaud E, et al. Among authors: yin ja. Blood. 1999 Dec 1;94(11):3694-701. Blood. 1999. PMID: 10572081 Free article. Clinical Trial.
Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
Geissler K, Yin JA, Ganser A, Sanz MA, Szer J, Raghavachar A, Hoelzer D, Martinez C, Taylor K, Kanz L, To LB, Archimbaud E. Geissler K, et al. Among authors: yin ja. Ann Hematol. 2003 Nov;82(11):677-83. doi: 10.1007/s00277-003-0737-7. Epub 2003 Oct 3. Ann Hematol. 2003. PMID: 14530872 Clinical Trial.
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Sun Y, Theodorakis MJ, Tendera M, Tucker L, Tuomilehto J, Wei Y, Yang W, Wang D, Hu D, Pan C; ACE Study Group. Holman RR, et al. Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886. doi: 10.1016/S2213-8587(17)30309-1. Epub 2017 Sep 13. Lancet Diabetes Endocrinol. 2017. PMID: 28917545 Free article. Clinical Trial.
An arrayed genome-wide perturbation screen identifies the ribonucleoprotein Hnrnpk as rate-limiting for prion propagation.
Avar M, Heinzer D, Thackray AM, Liu Y, Hruska-Plochan M, Sellitto S, Schaper E, Pease DP, Yin JA, Lakkaraju AK, Emmenegger M, Losa M, Chincisan A, Hornemann S, Polymenidou M, Bujdoso R, Aguzzi A. Avar M, et al. Among authors: yin ja. EMBO J. 2022 Dec 1;41(23):e112338. doi: 10.15252/embj.2022112338. Epub 2022 Oct 18. EMBO J. 2022. PMID: 36254605 Free PMC article.
Novel regulators of PrPC biosynthesis revealed by genome-wide RNA interference.
Heinzer D, Avar M, Pease DP, Dhingra A, Yin JA, Schaper E, Doğançay B, Emmenegger M, Spinelli A, Maggi K, Chincisan A, Mead S, Hornemann S, Heutink P, Aguzzi A. Heinzer D, et al. Among authors: yin ja. PLoS Pathog. 2021 Oct 27;17(10):e1010013. doi: 10.1371/journal.ppat.1010013. eCollection 2021 Oct. PLoS Pathog. 2021. PMID: 34705895 Free PMC article.
Two conserved epigenetic regulators prevent healthy ageing.
Yuan J, Chang SY, Yin SG, Liu ZY, Cheng X, Liu XJ, Jiang Q, Gao G, Lin DY, Kang XL, Ye SW, Chen Z, Yin JA, Hao P, Jiang L, Cai SQ. Yuan J, et al. Among authors: yin ja. Nature. 2020 Mar;579(7797):118-122. doi: 10.1038/s41586-020-2037-y. Epub 2020 Feb 26. Nature. 2020. PMID: 32103178
107 results